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ABSTRACT

Major depressive disorder (MDD) or depression is a heterogeneous mental illness which have direct effect on patient’s
behavior and cognition; causing constant feeling of unhappiness and loss of concern in earlier enjoyed events. Vortioxetine
(VOR) is a new atypical serotonergic antidepressant reported for the treatment of major MDD and has its use in various
psychological disorders. Despite its therapeutic potential, it has poor water solubility which creates problem in delivery.
Nanocrystal based orally disintegrating tablets (ODTs) are proposed to enhance water solubility and dissolution rate of
VOR. Nanosuspension was prepared by nanoprecipitation method after optimizing various parameters. The formulated
nanosuspension was effectively converted to solid powder by the lyophilization technique with emphasis on parameters
like nature/concentration of cryoprotectants. Prepared nanocrystals were characterized for solid state of drug present,
morphology and size after re-dispersion. The powders were then subsequently compressed into ODTs and dissolution
profiles of the tablets were compared. The dissolution profile of the ODTs prepared from nanocrystals showed superior
dissolution profile in comparison to ODTs prepared from untreated drug.
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5HT1B respectively[6]. It acts as a serotonin reuptake
inhibitor and also has serotonin receptor modulating
activity. Mode of action for VOR is not fully understood
but it is hypothesized that VOR binds with a greater
affinity to the serotonin transporter and its antidepressant
actions are considered to be secondary; due to the increase
in serotonin levels in the brain as a result of reuptake
inhibition[7]. Despite its potential in the treatment of MDD,
main hurdle in delivery of this drug candidate is its poor
water solubility. Vortioxetine was approved in 2013 by
Food and Drug Administration for the MDD management
under the brand name of Brintellix having drug as a
hydrobromide salt[8]. Due to the basic nature of drug as
well as comprising of secondary amine functional group
(8.85 pKa value of N1), various salt forms can easily be
made with acids including fumarate, HCl and many more.
However these salt forms are very prone for conversion to
different polymorphic forms which again have possibilities
to change physicochemical properties of developed salt[9].
Thus there is a basic need to work upon some other
solubility enhancement techniques for this drug candidate.

INTRODUCTION
Major depressive disorder (MDD) or depression is a
heterogeneous mental illness which have direct effect on
patient’s behavior and cognition; causing constant feeling
of unhappiness and loss of concern in earlier enjoyed
events[1]. Depression recurrently goes unrecognized
and untreated; and may be a causative factor of suicidal
attempts and impaired interpersonal relationship in society
as well as at work space. People may experience it once
in life or as multiple episodes in lifetime[2]. Depression is
one of the very common psychological disorder and as
per the reports of World Health Organization (WHO),
worldwide 350 million people suffer from depression,
that is closer to about 5% of the world’s population[3]. It
is one of the leading cause of disability and its prevalence
is more in women as compared to men[4]. The treatment of
MDD includes different categories of antidepressants such
as selective norepinephrine reuptake inhibitors (SNRI),
selective serotonin reuptake inhibitors (SSRI), tricyclic
antidepressants, atypical antidepressants, etc.[5].
Vortioxetine (VOR) is a new atypical serotonergic
antidepressant reported for the treatment of MDD and
has its use in various other psychological disorders. VOR
works as antagonist of 5-HT3, 5-HT1D, 5-HT7 and has
agonist and partial agonist activities for 5-HT1A and

Physical/chemical modification and formulation
based approaches are also in use since long ago for
solubility enhancement, amongst which size reduction
is one of the basic concept, having prime importance in
the pharmaceutical field. Reduced particle size helps in
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improving bioavailability of compounds by overcoming
erratic drug absorption[10]. Nanoparticles are known to
improve performance of drug candidates in a variety of
dosage forms. Modified performance of this delivery
system include solubility enhancement, delivery to specific
site and many more[11]. Nanocrystal is one amongst the
best known techniques for solubility enhancement which
also offers the various advantages over the other solubility
enhancement techniques.

2.1.

Materials

2.2.1.

Drug-excipient compatibility studies

Binary ratios (1:1) of VOR -excipients were prepared
and were checked for any kind of chemical interaction
using Fourier-transform infrared spectroscopy (FTIR)
spectroscopy. All the measurements were done using
Alpha Opus 7.5 instrument (Bruker, USA). The mixtures
were examined following formation of KBr pellet. In this
method, the pellets were formed by compressing about
2 mg of mixture triturated along with moisture free KBr
using hydraulic press. These were then analyzed in the
range of 4000-400 cm-1.

2.2.2.

Owing to the advantages offered by nanocrystal, it
is proposed to formulate orally disintegrating tablets
(ODTs) of VOR to enhance its water solubility as well as
the rate of dissolution[16]. Nanosuspension of VOR was
prepared by nanoprecipitation method after optimizing
various parameters. The prepared nanosuspension was
effectively converted into solid powder with specific
focus on parameters affecting final product like nature
and concentration of cryoprotectants. Nanocrystalline
dispersion was characterized for state of drug present,
morphology and size after redispersion. Subsequently the
lyophilized powders obtained were compressed to ODTs
and the rate of dissolution were compared.

Experimental section

Methods

The drug- excipient compatibility studies were done by
means of differential scanning calorimetry (DSC)[17]. Binary
ratios of VOR-excipients were prepared and were checked
for any kind of interactions using an Indium calibrated
auto DSC basic unit (NETZSCH) with provision of a
refrigerated cooling system was used for the measurements
during the study. Approximately 1.5- 4.0 mg of different
binary mixtures were weighed in an aluminum pan and
was allowed to heat from 0 °C to 250 °C, using nitrogen
as an inert gas. In this study, the standard (reference) used
was empty DSC pan.

Nanocrystals are particles of pure drug in nano size
range stabilized with the aid of little amount of stabilizer.
These differ from other nanomaterials in a way that these
are composed of active pharmaceutical ingredient contrary
to serving as drug carriers by virtue of excipients that is
usually the case with micelles, liposomes and polymeric
nanoparticles[12]. Some authors have expanded this
definition of nanocrystals to include amorphous form of
drug as well, and accept both crystalline and amorphous
form in its definition[13,14]. Drug particles are simply covered
with layer of surfactant or polymer which acts as a stabilizer
and omits the requirement of any other excipients. Because
of its size in nanometer range, nanosuspension offers a
high surface area to volume ratio, improving saturation
solubility as well as rate of dissolution[15].

2.

2.2.

Preparation of nanosuspension

Conventional nanoprecipitation method was tried
as preparation method for VOR nanosuspension. The
nanoprecipitation of VOR was achieved by the solventantisolvent technique. The solvents were selected from
dichloromethane (DCM), methanol, ethanol and acetone.
Different surfactants screened as stabilizer were Pluronic®
F-68, Pluronic® F-127, HPMC, TPGS and SLS alone as
well as in combination with each other. Various material
attributes and processing conditions viz. selection of
solvent, stabilizer type, drug to surfactant ratio, solvent to
anti-solvent ratio and stirring speed were optimized to get
preferred particle size and PDI[18]. One variable at a time
approach was used in order to optimize the formulation
conditions. Table 2 summarizes all the attempts made to
get acceptable size and PDI (polydispersity index). All the
batches were formulated in triplicates (n=3).
2.2.3.

VOR was received as a gift sample from Amneal
pharmaceuticals Pvt. Ltd. (India). Pluronic® F-127,
Sodium lauryl sulphate (SLS), Trehalose dihydrate (TD),
Hypromellose (HPMC) and Pluronic® F-68, were procured
from Sigma-Aldrich (Germany). Maltose monohydrate
(MM) and Sorbitol were supplied by HiMedia Laboratories
(Mumbai, India). Disodium hydrogen phosphate, sodium
chloride and potassium dihydrogen phosphate were
procured from Fischer scientific (USA). Mannitol was
procured from Spectrochem Pvt. Ltd. (Mumbai India).
Water used in all experiments, was obtained from a Milli®-Q
Biocel, Millipore® (USA) assembly. All other solvents and
reagents used in formulation were of analytical grade and
used as such without further purification.

Solidification of nanosuspension

Different types of techniques are used for solidification
in order to avoid the physical and chemical instability
issues related to drug. Solidification leads to hindered
particle motion and reduced chances of collision which
ultimately results in physical stability of drug. Also, the
elimination of water during solidification significantly
decreases the most of the chemical reactions responsible
for chemical instability of drug. Furthermore, it is well
known that the chemical and physical interactions occurs
rapidly in liquid state in comparison to solid state, and thus
solidification results in stabilization of the system. Various
solidification techniques like freeze drying, hydrogel
formation, spray drying, palletization and electrospinning
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2.2.4.3. Characterization of physical/chemical state
of drug present

had been explored by the researchers that are suitable to
convert nanosuspension into nanocrystals[19]. From all of
these techniques freeze drying and spray drying are the
ones which have been explored much more by scientists
working in this area[19,20]. Nanosuspension of the optimized
batch was lyophilized at constant temperature and
pressure of -80 °C and 5 mT (ilshinBioBase, South Korea)
respectively. Mannitol, maltose, TD, and D-sorbitol were
screened for their use as cryoprotectant[19]. Concentrations
of 1%, 2%, 5%, and 10% of aforementioned cryoprotectants
were screened utilizing freeze-thaw studies to optimize
the one with better effect. Nanosuspension with/without
selected cryoprotectants was subjected to freeze and thaw
cycle at -80 ºC for 72 h at room temperature respectively.
After thawing, particle size, PDI and zeta potential of the
formulation was determined. The cryoprotectants providing
Sf/Si ratio (where, Sf is the final particle size after thawing,
and Si is initial particle size before freezing) less than 1.3
were selected for further optimization[21]. Finally samples
were lyophilized following freezing at -80 °C[22, 23].

2.2.4.

X-ray diffraction (XRD) and DSC were carried out to
verify the state of drug present (amorphous or crystalline)
in final lyophilized nanocrystals. The X-ray powder
diffractograms were recorded at room temperature by a
diffractometer (GNR APD 2000 Pro) using a Modern SAX
software. The sample was spread evenly on a holder and
scanned for 2θ range of 3-40° with a step size of 0.01 and
at a scan speed of 0.1 sec. DSC and FTIR analysis was
performed with conditions mentioned in section 2.2.1.

2.2.4.4. Drug assay
Analytical method for drug was validated using high
performance liquid chromatography (HPLC) Agilent
system. C18 Kromasil column (250 mm x 4.6 mm, 5μ)
was utilized with mobile phase of methanol: ammonium
acetate buffer (pH 4) in ratio 75:25. Analysis was done at
230 nm with flow rate of 1 ml/min and injection volume of
5µL. Accurately weighed lyophilized sample (5 mg) was
solubilized in 1 ml of Milli®-Q by subjecting to vortexing
and sample was then analyzed (after possible dilution
required) for drug assay by validated analytical method.
The dissolved sample was filtered with 0.2 µm filter before
analysis.

Formulation characterization

2.2.4.1. Analysis of particle size, PDI and zeta
potential
A known quantity of lyophilized nanocrystals was
dissolved in 5 ml distilled water (Milli®-Q water) and
shaken properly so as to get a uniform dispersion. This
was then analyzed using Zeta sizer which is based on the
principle of dynamic light scattering (Nano ZS series,
Malvern) for size and PDI. Zeta potential was measured
with the help of same instrument. All the measurements
were done in triplicate (n=3).

2.2.5 Formulation
Tablets (ODTs)

of

Orally

Disintegrating

2.2.5.1. Evaluation of flow and compressibility index
Bulk density, tapped density as well as angle of
repose were determined to assess flow properties and
compressibility behavior of final blend prepared. Bulk
and tapped density were determined by the method as
previously described[24]. The following equations were used
to calculate the compressibility index and Hausner’s ratio
(where ρTapped is tapped density and ρBulk corresponds
to bulk density).

2.2.4.2. Particle morphology and surface roughness
analysis
The surface morphology analysis of lyophilized
formulation was carried out using Scanning electron
microscope (SEM). Study was conducted for analysis of
particle surface morphology of pure drug, physical mixture
and lyophilized nanocrystals. The samples were prepared
by mounting the powder onto a metal stab with the help
of a double sided conductive adhesive tape and platinum
coated sputter in an inert gas atmosphere and then the
SEM analysis (JSM-7600F, Jeol) were carried out at an
excitation voltage of 3 kV.

Hausner's ratio

Angle of repose which is the measure of flow property
of powder is an angle formed by the edge of pile with
the horizontal base after falling of sample powder from a
funnel which is fixed at particular height from horizontal
base. Height of the cone formed (h) and radius of the base
(r) were measured and angle of repose was calculated by
the following equation.

To determine the changes in surface roughness of
nanocrystals in comparison to the untreated drug, Atomic
Force Microscopy (Multimode 8, Bruker, USA) was done.
Scan speed was set at 0.5 Hz and scan sizes were taken from
100 nm to 800 nm. Before analysis, sample was prepared
by dispersing sufficient amount of sample in water and
glass slides were prepared by drop casting method. The
data was represented in topographic and phase imaging
mode. After drop casting, the sample was subsequently
dried at ambient conditions in order to prevent movement
of particles.
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2.2.5.2. Preparation of ODTs

Weight variation was studied by taking 20 tablets
(selected on random basis) and calculating average weight
followed by comparison of weights from individual tablets
with average weight.

Tablet blend of lyophilized nanocrystals as well as
untreated drug was prepared along with excipients for
the preparation of ODT (Table 1) by direct compression
technique. All the excipients were sieved from a coarse
sieve of 40 mesh size. After geometric mixing of drug dose
with all the excipients, powder blend was mixed with talc
and magnesium stearate as lubricants for 5 mins. Finally,
the dry mixture was compressed by means of 6.00 mm flat
punches on 8 station rotary tablet compression machine
(Kambert, Gujarat, India).

Friability testing was done utilizing Roche friabilator.
Pre-weighed tablets were taken and subjected to 100
revolutions in the friabilator, dropping the tablets from
6 inches in each revolution. Friability of tablets was
determined by the equation mentioned below.

Table 1: Composition of ODT

Where, W1 is initial weight and W2 final weight.

Excipient

Weight Per Tablet

VOR / Lyophilized
nanocrystals

5 mg or equivalent to 5 mg of
drug

Mannitol

10 mg

Pharmaburst 500

85 mg

Talc

1.5 %

Mg Stearate

1.5 %

In vitro dissolution study for ODTs formulated using
lyophilized nanocrystals and untreated drug was performed
in 500 ml of dissolution medium (SSF and 0.1 N HCl).
The temperature of the medium during the experiments
was kept 37 ± 0.5 ºC and rotational speed of 50 rpm. The
sample (5ml) were withdrawn at the time intervals of 5,
10, 15, 20, 25, 30, 40, and 60 minutes and at each time
point the fresh dissolution medium was used to replace
withdrawn sample. Withdrawn samples were subjected for
analysis a using HPLC method as described in preceding
section.

2.2.5.3 Evaluation of ODTs
Evaluation of prepared ODTs for hardness (by
Monsanto hardness tester), weight variation, friability, and
dissolution profile and disintegration time was performed.
Briefly, three tablets from each of the batch were randomly
selected and crushing strength required was determined by
hardness tester in kg/cm2 [25-28].

RESULTS AND DISCUSSION
3.1.

Drug-excipient compatibility studies

HPMC, SLS, Pluronic® F-127, Pluronic® F-68 and
TPGS were taken for screening of physically compatible
stabilizer. DSC curves for drug revealed three endothermic
events at 100 °C, 228 °C and 233 °C corresponding to
the peak of moisture and two polymorphic forms of drug.
Binary mixtures prepared with HPMC, Pluronic® F-68
and Pluronic® F-127 showed retention of drug peak for
single polymorph along with characteristic peaks of their
own (Figure 1). In case of SLS and TPGS mixtures drug
peak was found to be absent. For further clarification, hot
stage microscopy (HSM) was performed (Figure 2) and
events visualized suggested that the solubilization of drug
particles in melt of both these stabilizers which clarifies
the reason for absence of endothermic event in these cases.

Wetting time and water absorption ratio of the prepared
tablets were also determined that indicate the ease of
disintegration of tablet in the buccal cavity. Briefly, a 8.5
cm piece of folded (twice) tissue paper was placed in a
petri dish (8.5 cm internal diameter) containing about 8 mL
of aqueous eosin dye solution (0.5%). Each tablet (n=6)
was then placed on the tissue paper carefully and the time
required for the dye solution to appear on the upper surface
of tablet indicating complete wetting was recorded as the
wetting time. After that, the wetted tablet was weighed
and the water absorption ratio (R) was calculated using
following equation.

Results obtained for FTIR analysis showed retention
of all the peaks for drug (at 3284 cm-1, 2929 cm-1,
1473 cm-1, 1229 cm-1, 762 cm-1 corresponding to N-H
stretching, C-H stretching, C=C stretching, C-H stretching,
C-S stretching respectively) in all of the prepared binary
mixtures of the drug with excipients (Figure 3). Peak
broadening was observed for some binary mixtures which
could be due to the H-bonding interactions[33]. Hence all
the selected excipients were found to be both physically
as well as chemically compatible with the drug and thus
were taken further for screening of stabilizer by preparing
preliminary batches of nanosupension.

Where, Wt is the tablet weight after complete wetting and
Wo is the initial weight of the tablet[29-31].
Disintegration time was determined by a tailored
disintegration method (n=6)[32]. Briefly, about 10 ml of
water was taken in petri dish and tablet was cautiously
placed in the center of the Petri dish. The time required for
the tablet to wholly disintegrate was noted by means of a
stop watch.
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screened, SLS and Pluronic® F-127 provided smaller size
and PDI (Table 2) as compared to others and were taken
further. During storage, nanosuspension containing SLS
as stabilizer showed lower increase in size as compared
to batch containing Pluronic® F-127 at room temperature.
Therefore considering changes in particle size of prepared
nanosuspension SLS was selected for further study. SLS is
an ionic stabilizer which involves the adsorption of ionic
charges on the surface of particles resulting in mutual
repulsive forces between particles. Anionic nature of
SLS provides the higher electrostatic repulsive force as
compared to other stabilizers whereas Pluronics are known
for steric stabilization provided by them[34].

Fig. 1: DSC thermograms of A: Drug, B: Drug + HPMC, C: Drug
+ TPGS, D: Drug + Pluronic® F-68, E: Drug + Pluronic® F-127
and F: Drug + SLS

Table 2: Effect of various processing conditions on size and PDI
of drug nanocrystals
Average
particle size
(in nm)

PDI

DCM

340.18 ± 26.1

0.444 ± 0.21

Methanol

469.1 ± 41.3

0.552 ± 0.21

Nano-precipitation method

Solvent

Drug
concentration

Fig. 2: HSM images of A: SLS and drug at A1: Initial (32 °C),
A2: 100 °C, A3: 200 °C, A4: 240 °C; B: TPGS and drug at B1:
Initial (32 °C), B2: 40 °C, B3: 100 °C, B4: 200 °C

Solvent to
anti-solvent
ratio

Stabilizer

Drug to
stabilizer
ratio

Fig. 3: FTIR spectra of A: Drug, B: Drug + Pluronic® F-68, C:
Drug + Pluronic® F-127, D: Drug + SLS, E: Drug + TPGS and
F: Drug + HPMC

3.2.

Preparation of nanosuspension

3.2.1.

Screening of stabilizers

Ethanol

327.0 ± 21

0.425 ± 0.42

Acetone

212.2 ± 22.1

0.123 ± 0.24

1 mg/10ml

410.3 ± 31.4

1.00 ± 0.23

2 mg/10ml

339.1 ± 46.7

0.588 ± 0.5

3 mg/10ml

380.9 ± 17.5

0.512 ± 0.33

4 mg/10ml

332.9 ± 35.2

0.384 ± 0.57

5 mg/10ml

203 ± 11.7

0.184 ± 4.74

1:3

145.1 ±13

0.428 ± 0.23

1:5

215.9 ± 9.35

0.173 ± 0.31

1:10

385.5 ± 11.8

0.193 ± 0.24

Pluronic®
F-68

415.0 ± 9.7

0.970 ± 0.76

Pluronic®
F-127

203 ± 11.7

0.184 ± 0.3

SLS

220.9 ± 21.3

0.153 ± 0.16

TPGS

334.6 ± 31

0.382 ± 0.29

HPMC

Visible
precipitate

-

0.5:1

456.3 ± 18.1

0.535 ± 0.62

1:5

615.2 ± 31.2

0.518 ± 0.21

1:1

237.2 ± 8.12

0.213 ± 0.31

1:3

528.7 ± 25.6

0.414 ± 0.17

3.2.2. Screening of solvent and solvent to antisolvent ratio
The solvent for formulation preparation were
screened from methanol, acetone, ethanol, and DCM.
Nanosuspension made with methanol showed visible
precipitate probably as the drug was least soluble in
methanol. Amongst all the solvents tried, acetone provided
the size and PDI in acceptable range and hence acetone
was selected for further for optimization of solvent: antisolvent ratio.

For screening of stabilizers one variable at a time
approach was used in which one process/ formulation factor
was changed at a time while keeping all other parameters
constant. Nanosuspension formulation was commenced on
600 rpm by screening stabilizers namely Pluronic® F-127,
Pluronic® F-68, SLS, HPMC and TPGS. Particle size and
polydispersity index (PDI) were main parameters based
on which screening was done. Amongst all the stabilizers
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3.2.5.

Solvent (any organic solvent used to dissolve drug) to
anti-solvent (aqueous phase) ratio was optimized by taking
three ratios viz. 1:3, 1:5 and 1:10. As the supersaturation
is an important phenomenon which depends upon the
evaporation and miscibility of solvent in anti-solvent used,
it was important to assess this parameter. From all the
ratios screened 1:5 ratio gave adequeate size and PDI and
was taken further for optimization of other parameters.

3.2.3.

Optimization of type as well as concentration of
cryoprotectants often requires studies with large number
of formulations. Even though lyophilization process is
expensive, freeze–thaw studies are rapid and quicker
in comparison to lyophilization and thus screening
of type and concentration of cryoprotectants can be
carried out easily. According to freeze-thaw study, an
effective cryoprotectant is the excipient which protects
formulation during the freezing step of lyophilization and
the same is determined by calculating Sf/Si ratio (where
Sf and Si are final size and initial size of the formulation
respectively)[23, 35].

Optimization of drug to stabilizer ratio

The effect of various concentrations of stabilizer
on the particle size and PDI was studied by preparing
nanosuspension using 0.5:1, 1:1, 1:3 and 1:5 ratio of drug
to stabilizer respectively. It was found that, the 1:1 ratio of
drug to stabilizer resulted in nanosuspension with smallest
size and PDI. This could be due to the fact that in case of
0.5:1, 1:3 and 1:5 ratio, the concentration of stabilizer was
sufficient to initiate solubilization phenomenon. On the
basis of these results 1:1 drug to stabilizer ratio with SLS
was chosen as optimized stabilizer level.

3.2.4.

Lyophilization of optimized nanosuspension

The cryoprotectants were screened in initial trial in
the concentration ranges of 1%, 2%, 5%, and 10%. After
carrying out a freeze-thaw study the ratio of the initial size
(Si) to the final size (Sf) was plotted against individual
group and the cryoprotectant that gave the smallest ratio
was finally selected. Amongst all the cryoprotectants, 1%
trehalose was selected as final cryoprotectant to work with
(Figure 5).

Optimization of stirring speed

Effect of stirring speed on particle size and PDI of
prepared nanosuspension was observed and optimized
batches were obtained at 600 rpm speed as other rpm
screened (400, 800, 1000) resulted in visible precipitate.
(Figure 4) shows original graph for size distribution by
intensity using DLS technique.

Fig. 5: Screening of cryoprotectants by freeze thaw studies

3.2.6.

Formulation characterization

3.2.6.1. Particle size and zeta potential analysis
The lyophilized nanocrystals (particularly weighed
amount) was re-dispersed in Milli® Q water and particle
size, zeta potential, PDI was determined using DLS
method. Average particle size, PDI and zeta potential
of finally optimized nanosuspension were found to be
241.6 ± 7.9 nm, 0.163 ± 0.12 and -7.8.1 ± 0.53 mV
respectively. Both the size as well as PDI were obtained
in acceptable range[36]. Zeta potential plays an important
role in the stability of nanosuspension and is a measure of
electrostatic stabilization.

Fig. 4: Size distribution of VOR nanosuspension prepared
utilizing optimized parameters with A: SLS and B: Pluronic®
F127

3.2.7.2 Particle morphology and surface roughness
analysis
SEM analysis was carried out to study the surface
morphology of lyophilized nanocrystals, untreated drug,
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physical mixture, and lyophilized nanocrystals without any
cryoprotectant. Irregularities on the surface was found in
case of untreated drug, while the lyophilized formulation
was found to be smoother in appearance. Morphology
obtained in lyophilized nanocrystals was quite different
from appearance of physical mixture.
Surface roughness analysis of lyophilized nanocrystals
in comparison to unprocessed drug and physical mixture
was performed with the help of Atomic Force Microscopy
(AFM) AFM analysis results showed that particle size of
the untreated drug was more than lyophilized nanocrystals.
(Figure 6) presents the AFM images of the untreated drug,
physical mixture, lyophilized nanocrystals and lyophilized
nanocrystals without cryoprotectants. The results revealed
that both the particle size as well as surface roughness of
untreated drug was found to be greater than lyophilized
nanocrystals.

Fig. 7: A: DSC thermograms of A1: Drug, A2: SLS, A3:
Trehalose, A4: Lyophilized nanocrystals and B: XRD spectra of
B1: Drug, B2: Lyophilized nanocrystals, B3: Physical mixture

Fig. 8: FTIR spectra of A: Lyophilized nanocrystals, B: Drug and
C: Physical mixture

3.2.7.4 Analysis of drug content
The lyophilised sample was analysed for the drug
content with validated analytical method described in
previous section by adding pre-weighed sample (1 mg/
ml) to solvent. Drug assay was calculated for lyophilized
nanocrystals and the value was found to be 98.73 ±1.2
%. Experiment was conducted in triplicate and result is
expressed as mean ± SD.

Fig. 6: A: SEM images of A1: Drug, A2: Physical mixture, A3:
Lyophilized nanocrystals, A4: Lyophilized nanocrystals without
cryoprotectant; B: AFM images of B1: Drug, B2: Physical
mixture, B3: Lyophilized nanocrystals and B4: Lyophilized
nanocrystals without cryoprotectant

3.2.7.3 Physical/chemical state characterization

3.2.8 Formulation of Orally Disintegrating Tablets
(ODTs)

DSC and XRD were conducted to assess the physical
state of drug present. Results obtained from DSC
analysis of lyophilized nanocrystals revealed absence of
endothermic peak for drug. Probable reason for that could
be either decrease in crystallinity of drug or merging of
small endothermic event of drug in thermal event of SLS.
Further XRD was conducted to confirm the physical
state and results obtained suggested absence/decrease in
peak intensity for drug, which again indicates decrease
in crystallinity of the drug (Figure 7). Previously authors
have reported drug amorphization after freeze dried
processing[37].

Evaluation of powder characteristics was carried
out and bulk density, tapped density, angle of repose,
Hausner’s ratio, and compressibility index, were calculated
(Table 3). Values obtained for Angle of repose, Hausner’s
ratio and Carr’s index suggested that powder blend possess
good flow properties as well as compressibility.
Table 3: Evaluation of powder blend for compressibility and
flow properties

FTIR analysis of lyophilized nanocrystals revealed
presence of all the peaks of drug which shows no chemical
modifications after all the processing (Figure 8).

17

Parameter

Values obtained

Bulk density

0.381 g/ml

Tapped density

0.457 g/ml

Angle of repose

28°

Hausner’s ratio

1.19

Carr’s index

16 %

NANOCRYSTAL BASED ORALLY DISINTEGRATING TABLETS OF VORTIOXETINE

3.2.8.1 Evaluation of ODTs
Prepared ODTs were evaluated for hardness, wetting
time, water absorption ratio, disintegration time and weight
variation (Table 4). Parameters tested were found to be in
the pharmacopoeial limits. Weight variation was found to
be less than 10% whereas friability values were less than
1%. Hardness was found to be 3.5 ± 0.27 kg/cm2 whereas
wetting time and water absorption ratio (R) was found
to be 10.5 ± 1.37 sec and 92.16 ± 15.04 % respectively.
Images acquired at different time points during wettability
test are depicted in (Figure 9). Disintegration time was in
the range of 19.8 ± 0.15 sec[38, 39].

Fig. 10: Dissolution studies of ODTs prepared with untreated
drug and Lyophilized nanocrystals in A: 0.1 N HCl and B: SSF

CONCLUSION
Nanosuspension formulation of drug VOR (with
average particle size, PDI and zeta potential values of 215.9
± 9.35 nm, 0.123 ± 0.31, -19.3 ± 2.24 mV respectively) was
successfully prepared by nano-precipitation method with
SLS as a surfactant. Nanosuspension was lyophilized with
1% trehalose as cryoprotectant of choice. The lyophilised
powder was characterized using DSC, FITR, SEM, AFM
and XRD analysis to asess surface morphology, roughness,
physical state of drug present and chemical modifications.
In vitro release studies revealed that about ~97% of release
of drug for the ODTs prepared with nanocrystals as
compared to unprocessed drug (~60%) within same time.
Thus the overall developed formulation found to have
potential for solubility enhancement of drug VOR using
nanoprecipitation technique.

Table 4: Characteristics of prepared tablets
Parameters

Tablet prepared with
lyophilized nanocrystals

Hardness (kg/cm2)

3.5 ± 0.27

Thickness (mm)

3.5 ± 0.35

Weight variation (%)

< 7.5%

Disintegration time (sec)

19.8 ± 0.15

Friability (%)

1%

Wetting time (sec)

10.5 ± 1.37
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ABBREVIATIONS
AFM: Atomic force microscopy
BCS: Biopharmaceutical classification system

Fig. 9: Images from wettability testing at A: initial, B: 5 sec, C:
8 sec and D: 11 sec after complete wetting

CMC: Critical micelle concentration

3.2.8.2 In-vitro release study

DCM: Dichloromethane

In vitro drug release study was carried out for prepared
ODT formulations. Along with it ODT compressed using
untreated drug was also compared. Results are shown
in (Figure 10). Drug release of ODTs formulated using
lyophilized nanocrystals was found to be more as compared
to ODTs formulated using the untreated drug in SSF due
to solubility advantage provided by nanocrystals. Whereas
dissolution profile for both these ODTs formulation was
found to be, approximately higher in 0.1N HCl increase
in SSF medium in comparison with untreated verses
lyophilized ODTs was prominent as well. Higher release
in HCl media could be attributed to high solubility of drug
at lower pH.

DSC: Differential scanning calorimetry
HPH: High-pressure homogenization
HPMC: Hypromellose
ICH: International conference on harmonization
SSF: Simulated salivary fluid
PDI: Polydispersity index
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